Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  title={Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.},
  author={S B Hanauer and Brian G Feagan and Gary R. Lichtenstein and Lloyd F Mayer and Stefan Schreiber and Jean Fr{\'e}d{\'e}ric Colombel and Daniel Rachmilewitz and D. Wolf and Allan D. Olson and Weihang Bao and P. R. Rutgeerts},
  volume={359 9317},
BACKGROUND We did a randomised controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn's disease who respond to a single infusion of infliximab. METHODS 573 patients with a score of at least 220 on the Crohn's disease activity index (CDAI) received a 5 mg/kg intravenous infusion of infliximab at week 0. After assessment of response at week 2, patients were randomly assigned repeat infusions of placebo at weeks 2 and 6 and then every 8 weeks… CONTINUE READING
Highly Influential
This paper has highly influenced 60 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 1,100 extracted citations


Publications referenced by this paper.
Showing 1-10 of 27 references

Malignancy following Remicade therapy : incidence and characteristics

  • A Sachmechian, E Vasiliauskas, M Abreu
  • Gastroenterology
  • 2001

Tuberculosis occurring in patients receiving the anti - TNF agent infliximab

  • D Baker, J Clark, G Keenan, S Jones
  • Arthritis Rheum
  • 2001

Complete bowel obstruction following initial response to infliximab therapy for Crohn ’ s disease : a series of a newly described complication

  • LS Toy, EJ Scherl, A Kornbluth
  • Gastroenterology
  • 2000

Similar Papers

Loading similar papers…